/clinical/,/clinical/cckm-tools/,/clinical/cckm-tools/content/,/clinical/cckm-tools/content/beacon-protocols/,/clinical/cckm-tools/content/beacon-protocols/supportive-care/,

/clinical/cckm-tools/content/beacon-protocols/supportive-care/name-122958-en.cckm

201711331

page

100

UWHC,UWMF,

Tools,

Clinical Hub,UW Health Clinical Tool Search,UW Health Clinical Tool Search,Beacon Protocols,Supportive Care

CSC SC Pamidronate Monthly Ver 11-20-17 (HL 1869)

CSC SC Pamidronate Monthly Ver 11-20-17 (HL 1869) - Clinical Hub, UW Health Clinical Tool Search, UW Health Clinical Tool Search, Beacon Protocols, Supportive Care


CSC SC PAMIDRONATE MONTHLY VER: 11-20-17 –  Properties
Cycle 1 –  11/22/2017 through 12/19/2017 (28 days), Planned
Day 1, Cycle 1 –  Planned for 11/22/2017
Treatment Conditions
Treatment Condition A
Dose in normal renal function = Pamidronate 90 mg IV. Dose modification may be required for renal dysfunction
(Creatinine greater than 3 mg/dL).
Hydration
sodium chloride 0.9 % infusion
at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Supportive Care Medications
pamidronate (AREDIA) in sodium chloride 0.9 % 250 mL bag
Intravenous, ONCE, 1 dose Starting when released
Cycle 2 –  12/20/2017 through 1/16/2018 (28 days), Planned
Day 1, Cycle 2 –  Planned for 12/20/2017
Treatment Conditions
Treatment Condition A
Dose in normal renal function = Pamidronate 90 mg IV. Dose modification may be required for renal dysfunction
(Creatinine greater than 3 mg/dL).
Hydration
sodium chloride 0.9 % infusion
at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Supportive Care Medications
pamidronate (AREDIA) in sodium chloride 0.9 % 250 mL bag
Intravenous, ONCE, 1 dose Starting when released
Cycle 3 –  1/17/2018 through 2/13/2018 (28 days), Planned
Day 1, Cycle 3 –  Planned for 1/17/2018
Treatment Conditions
Treatment Condition A
Dose in normal renal function = Pamidronate 90 mg IV. Dose modification may be required for renal dysfunction
(Creatinine greater than 3 mg/dL).
Hydration
sodium chloride 0.9 % infusion
at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
ZZtestonc,Andrew [2428787]
11/22/2017 11:24:47 AM Page 1 of 3
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org

Supportive Care Medications
pamidronate (AREDIA) in sodium chloride 0.9 % 250 mL bag
Intravenous, ONCE, 1 dose Starting when released
Cycle 4 –  2/14/2018 through 3/13/2018 (28 days), Planned
Day 1, Cycle 4 –  Planned for 2/14/2018
Treatment Conditions
Treatment Condition A
Dose in normal renal function = Pamidronate 90 mg IV. Dose modification may be required for renal dysfunction
(Creatinine greater than 3 mg/dL).
Hydration
sodium chloride 0.9 % infusion
at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Supportive Care Medications
pamidronate (AREDIA) in sodium chloride 0.9 % 250 mL bag
Intravenous, ONCE, 1 dose Starting when released
Cycle 5 –  3/14/2018 through 4/10/2018 (28 days), Planned
Day 1, Cycle 5 –  Planned for 3/14/2018
Treatment Conditions
Treatment Condition A
Dose in normal renal function = Pamidronate 90 mg IV. Dose modification may be required for renal dysfunction
(Creatinine greater than 3 mg/dL).
Hydration
sodium chloride 0.9 % infusion
at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Supportive Care Medications
pamidronate (AREDIA) in sodium chloride 0.9 % 250 mL bag
Intravenous, ONCE, 1 dose Starting when released
Cycle 6 –  4/11/2018 through 5/8/2018 (28 days), Planned
Day 1, Cycle 6 –  Planned for 4/11/2018
Treatment Conditions
Treatment Condition A
Dose in normal renal function = Pamidronate 90 mg IV. Dose modification may be required for renal dysfunction
(Creatinine greater than 3 mg/dL).
Hydration
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
ZZtestonc,Andrew [2428787]
11/22/2017 11:24:47 AM Page 2 of 3
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised:
 
11/2017CCKM@uwhealth.org

sodium chloride 0.9 % infusion
at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Supportive Care Medications
pamidronate (AREDIA) in sodium chloride 0.9 % 250 mL bag
Intravenous, ONCE, 1 dose Starting when released
Actions
Actions
Actions
ZZtestonc,Andrew [2428787]
11/22/2017 11:24:47 AM Page 3 of 3
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised:
 
11/2017CCKM@uwhealth.org